CUPPENS, Kristof

Email Alert RSS Feed

Profile

Full Name
CUPPENS, Kristof
Email
kristof.cuppens@uhasselt.be
 
Loading... 5 0 5 0 false
Loading... 6 0 5 0 false

Publications

Results 1-13 of 13 (Search time: 0.004 seconds).

Issue DateTitleContributor(s)TypeCat.
12023UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)Bar, Jair; Peled, Nir; Schokrpur, Shiruyeh; Wolner, Mirjana; Rotem, Ofer; Girard, Nicolas; Nana, Frank Aboubakar; Derijcke, Sofie; Kian, Waleed; Patel, Sandip; Gantz-Sorotsky, Hadas; Zer, Alona; Moskovitz, Mor; Metro, Giulio; Rottenberg, Yakir; Calles, Antonio; Hochmair, Maximilian; CUPPENS, Kristof; Decoster, Lynn; Reck, Martin; Limon, Dror; Rodriguez, Estelamari; Astaras, Christoforos; Bettini, Adrienne; Hafliger, Simon; Addeo, AlfredoJournal ContributionA1
22023The path forward in early-stage lung cancerCUPPENS, Kristof; Baas, PaulJournal ContributionA2
32023Liquid Biopsy in Early-Stage Lung Cancer: Current and Future Clinical ApplicationsVandekerckhove, Olivia; CUPPENS, Kristof; Pat, Karin; Du Pont, Bert; FROYEN, Guy; MAES, BrigitteJournal ContributionA1
42023Reliability of panel-based mutational signatures for immune-checkpoint-inhibition efficacy prediction in non-small cell lung cancerDonker, H. C.; CUPPENS, Kristof; FROYEN, Guy; Groen, H. J. M.; Hiltermann, T. J. N.; MAES, Brigitte; Schuuring, E.; Volders, P. -J.; Lunter, G. A.; van Es, B.Journal ContributionA1
52023Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 TrialCho, Byoung Chul; Lee, Jong Seok; Wu , Yi-Long; Cicin, Irfan; Dols, Manuel Cobo; Ahn, Myung-Ju; CUPPENS, Kristof; Veillon, Remi; Nadal, Ernest; Dias, Josiane Mourao; Martin, Claudio; Reck, Martin; Garon, Edward B.; Felip, Enriqueta; Paz-Ares, Luis; Mornex, Francoise; Vokes, Everett E.; Adjei, Alex A.; Robinson, Clifford; Sato, Masashi; Vugmeyster, Yulia; Machl, Andreas; Audhuy, Francois; Chaudhary, Surendra; Barlesi, FabriceJournal ContributionA1
62023Datopotamab Deruxtecan (Dato-DXd) plus Durvalumab ± Carboplatin in Advanced/mNSCLC: Initial Results from Phase 1b TROPION-Lung04Papadopoulos, K. P.; Bruno, D.; Kitazono, S.; Murakami, S.; Gutierrez, M.; Wakuda, K.; Spira, A.; CUPPENS, Kristof; Lovick, S.; Hepner, A.; Mak, G.; Waqar, S. N.Journal ContributionM
72022Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and TreatmentAgbarya, Abed; Shalata, Walid; Addeo, Alfredo; Charpidou, Andriani; CUPPENS, Kristof; Brustugun, Odd Terje; Rajer, Mirjana; Jakopovic, Marco; Marinca, Mihai, V; Pluzanski, Adam; Hiltermann, Jeroen; Araujo, AntonioJournal ContributionA1
82022Open-label, dose escalation, phase I/II study to assess safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDC*lung01 with or without anti-programmed death-1 (PD-1) treatment in patients with non-small cell lung cancer (NSCLC)Vansteenkiste, J. F.; Demedts, I.; Pons-Tostivint, E.; Biesma, B.; Borm, F.; Colinet, B.; CUPPENS, Kristof; Derijcke, S.; Greillier, L.; Juergens, J.; Moro-Sibilot, D.; Perol, M.; Sebastian, M.; Skrzypski, M.; Theelen, W.; Van De Kerkhove, C.; Collodoro, M.; Plumas, J.; Debruyne, C.; Sibille, A.Journal ContributionM
92022A randomized, multicentric phase II study of preoperative nivolumab plus relatlimab or nivolumab in patients with resectable non-small cell lung cancer (NEOpredict-Lung)Schuler, M. H. H.; CUPPENS, Kristof; Ploenes, T.; Vanbockrijck, M.; Wiesweg, M.; Darwiche, K.; Schramm, A.; MAES, Brigitte; Hegedus, B.; Schildhaus, H-U.; Hautzel, H.; Theegarten, D.; Baas, P.; Hartemink, K.; Du Pont, B.; Aigner, C.Journal ContributionM
102022Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinibAwada, Ahmad; Berghmans, Thierry; Clement, Paul M.; CUPPENS, Kristof; De Wilde, Bram; Machiels, Jean-Pascal; Pauwels , Patrick; Peeters , Marc; Rottey, Sylvie; Van Cutsem , EricJournal ContributionA1
112022A prospective, multicenter, noninterventional study of decision factors in the first-line treatment of metastatic non-small cell lung cancerSibille, Anne; Bustin, Frederique; Carestia, Luciano; Catala, Gaetan; Compere, Christophe; CUPPENS, Kristof; Colinet, Benoit; Coulon, Stephanie; De Brucker, Nele; Decoster, Lore; Decoster, Lynn; Demedts, Ingel; Derijcke, Sofie; Deschepper, Koen; Galdermans, Danny; Janssens, Annelies; Ocak, Sebahat; Oyen, Christel; Pat, Karin; Pieters, Thierry; Pruniau, Vincent; Surmont, Veerle; Vandekeere, Saar; Vansteenkiste, JohanJournal ContributionA1
122022Uncommon EGFR mutations on osimertinib, real-life data (UNICORN study): Updated results, brain efficacy, and resistance mechanismsBar, Jair; Peled, Nir; Schokrpur, Shiruyeh; Dudnik, Elizabeth; Wollner, Mira; Girard, Nicolas; Nana, Frank Aboubakar; Derijcke, Sofie; Kian, Waleed; Patel, Sandip P.; Sorotsky, Hadas Yocheved Gantz; Zer, Alona; Moskovitz, Mor; Metro, Giulio; Rottenberg, Yakir; Calles, Antonio; Hochmair, Maximilian; CUPPENS, Kristof; Decoster, Lynn; Addeo, AlfredoJournal ContributionM
132022HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitorsCUPPENS, Kristof; Baas, Paul; GEERDENS, Ellen; Cruys, Bert; FROYEN, Guy; Decoster, Lynn; THOMEER, Michiel; MAES, BrigitteJournal ContributionA1